Sermorelin, and the paperwork that comes with it.

What it is

Sermorelin is a synthetic peptide corresponding to a fragment of growth hormone-releasing hormone. It sits in the growth hormone secretagogue category alongside ipamorelin and CJC-1295. It is compounded and dispensed against a prescription; it is not an approved drug product.

The operational catch

Sermorelin remains compoundable, but the documentation and attestation requirements attached to it are heavier than for most of the category. Clinics that budget for the compound and not for the administrative process around it end up with a bottleneck between the consultation and the first shipment.

That is a workflow problem rather than a sourcing problem, which is why intake design matters more here than almost anywhere else on the menu. The paperwork has to be part of the patient flow, not an afterthought handled by whoever is at the desk.

Which pharmacy path applies

Typically 503(a) patient-specific compounding. Whether a 503(b) outsourcing facility prepares it, and in what presentation, varies and should be confirmed with the partner pharmacy rather than assumed from a catalog.

Menu fit

It is a common entry point for men's health and TRT practices, where the patient base already accepts injectable therapy and a monitoring cadence. In those settings the incremental operational lift is small, because the follow-up rhythm the compound requires is one the practice already runs.